Amylyx Pharmaceuticals (AMLX) Stock: $33 Target And Buy Rating

By Amit Chowdhry ● Jun 23, 2022
  • The shares of Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) have received a $33 price target from Citi. These are the details.

The shares of Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) have received a $33 price target from Citi. And Citi analyst Neena Bitritto-Garg increased the price target from $32 while maintaining a “Buy” rating on the shares. 

Bitritto-Garg adjusted the rating while citing that the market opportunity for Albrioza in Canada alone is relatively small with an estimated $100 million in sales at the peak. And the approval bodes well for the ongoing U.S. and European reviews.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.